Zacks Investment Research
29 Jun 2026, 13:51 UTC · 2h ago
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
29 Jun 2026, 13:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Krystal Biotech expects quarterly earnings of $1.80 per share, a 39.5% increase year-over-year, and revenues of $118 million, up 22.9%. — Strong projected growth in both top and bottom lines typically drives positive price action for mid-cap biotech firms.
+0.60The company's lead product, Vyjuvek, is experiencing strong patient uptake in the US and an expanding international launch. — Successful commercial execution of a primary revenue driver reduces risk and confirms the company's market viability.
+0.50Krystal Biotech is advancing a pipeline of therapies including KB407 for cystic fibrosis, KB408 for lung disease, and two ophthalmology candidates (KB801 and KB803). — Pipeline expansion creates future value-creation catalysts and diversifies the company's risk beyond a single product.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
The consensus EPS estimate for the current quarter has remained unchanged over the last 30 days. — A lack of upward revisions in earnings estimates often suggests a ceiling for near-term stock price momentum.
-0.20Which stocks this story touches
Shares soared due to strong commercial execution of Vyjuvek and a positive outlook for its gene therapy pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
